Long-lasting Spexin Could Spell the End of Obesity

Some researchers have suggested that the administration of spexin (a neuropeptide) may promote weight loss in humans. However, the neuropeptide has had limited success due to its short half-life in serum (i.e., it leaves the body too quickly). Our synthesized spexin cyclic analogues have much longer half-lives in serum, and this may address the concern.

• Our synthesized spexin cyclic analogues have much longer half-livesin serum, meaning that it won'tleave the body too quickly.
• In our animal study, it has proved that the analogues are very effective as it can reduce food intake and promote weight loss with much lower side effects when comparing to other drugs.

• Since these spexin cyclic analogues can stay longer in the body, the frequency of drug intakes or even the dosage might be significantly reduced that can benefit the user.

• The present invention can bepotentially used for treatingseveral metabolic diseases including type-II diabetes, non-alcoholic fatty liver disease and, most notably, obesity.

• US Patent No. US 10,376,555
• China Patent Publication No. CN 110506053 A
• European Patent Publication No. EP 3606948 A1